HRS-1358 for Advanced Breast Cancer
A Trial of HRS-1358 Tablets in Metastatic or Local Advanced Breast Cancer
- Age
- 18 – 75
- Sex
- Female
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 102 (estimated)
- Sponsor
- Shandong Suncadia Medicine Co., Ltd. · Industry
This trial is looking for women with advanced or metastatic breast cancer. Participants will take HRS-1358 alone or with another medication to assess safety and tolerability.
You may be able to join if
- I have been diagnosed with advanced or metastatic breast cancer.
- I am a postmenopausal woman or on ovarian suppression.
- I have received at least one line of endocrine therapy.
- I have a good performance status score.
- I have adequate organ functions.
- I can understand and agree to participate in the study.
You may not be able to join if
- I have been judged unsuitable for endocrine therapy.
- I have active brain metastasis with symptoms.
- I have a history of significant cardiovascular diseases.
- I have conditions affecting drug absorption or metabolism.
- I have an active autoimmune disease or a history of immunodeficiency.
- I have received similar drugs in the past.
- I am allergic to HRS-1358 ingredients.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe study is being conducted to evaluate the safety and tolerability of HRS-1358 monotherapy or combination with Dalpiciclib Isethionate Tablets in patients with metastatic or locally advanced breast cancer in order to estimate the Dose-Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and select the Recommended Phase 2 Dose (RP2D).
Loading trial locations…